Trial Information

Summary: Gog 0127v a phase ii evaluation of abi-007 (ind#55,974) in the treatment of persistent or recurrent squamous or non squamous cell carcinoma of the cervix

The purpose of this study is to determine the effectiveness of the investigational drug ABI-007 in treating cervical cancer and to determine the types and severity of side effects caused by treatment with this drug. ABI-007 is a modified form of paclitaxel, a drug which is effective in treating ovarian, uterine, and cervical cancer. ABI-007 is being developed to reduce the side effects that go along with treatment that includes paclitaxel.

Inclusion Criteria:

• Patients must have persistent or recurrent squamous or non-squamous cell carcinoma of the cervix with documented disease progression.
• All patients must have measureable disease
• Patients must have a performance status 0, 1, or 2.
• Patients must have had one priror systemic chemo regimen for managment of advanced, metastatic, or recurrent squamous or non-squamous cell carcinoma of the cervix

Exclusion Criteria:

• Patients with prior therapy with ABI-007 or any other taxane
• Patients who have recevied prior radiotherpay to any portion of the abdominal cavitiy or pelvis OTHER THAN for the treatment of cervical cancer within the last 5 years are excluded

If you would like to learn more about participating in this study, please send an e-mail message using the form below.